Stay updated with breaking news from Elad Sharon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Delivers Revenue Growth and Strong Margin Expansion in Both Fourth Quarter and Full Year Guides to Fiscal 2025 Revenue of Approximately $340 Million with Faster Gross Margin Growth and Doubling of...
Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.
<p style="text-align:start">In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab. These and other results of the analyses are presented as a proffered paper (Abstract LBA48) at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on Monday, October 23, by Sapna P. Patel, MD, chair of the SWOG melanoma committee and ...
Nature talks to experts about how mRNA is transforming medicine. Nature talks to experts about how mRNA is transforming medicine.